Corpus Intelligence IC Memo — HOSPITAL HIMA SAN PABLO FAJARDO 2026-04-26 14:08 UTC
IC Memo — HOSPITAL HIMA SAN PABLO FAJARDO
Investment Committee Memorandum | PR | 179 beds | Grade C | EBITDA uplift $1.1M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

HOSPITAL HIMA SAN PABLO FAJARDO

CCN 400125 | FAJARDO, PR | 179 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

HOSPITAL HIMA SAN PABLO FAJARDO is a 179-bed under-performing / distressed in FAJARDO, PR with $14.6M in net patient revenue and a -45.9% operating margin. The hospital serves a payer mix of 4.5% Medicare, 16.7% Medicaid, and 78.8% commercial.

Thesis: Undervalued. Our ML models identify $1.1M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -45.9% to -38.6% (+736bps).

Net Revenue HCRIS$14.6M
Current EBITDA COMPUTED$-6.7M
Operating Margin COMPUTED-45.9%
Occupancy HCRIS18.4%
Revenue / Bed COMPUTED$82K
Net-to-Gross HCRIS57.0%
Distress Probability ML62.3%

2. Market Context & Competitive Position

61
PR Hospitals
-8.8%
State Median Margin
37
Comparable Hospitals

PR has 61 Medicare-certified hospitals with a median operating margin of -8.8%. The target's margin of -45.9% places it below the state median. Among 37 size-comparable peers (90-358 beds), the median margin is -4.9%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (90-358), prioritizing same-state peers. 37 hospitals in the comp set.

HospitalStateBedsRevenueMargin
HOSPITAL HIMA SAN PABLO FAJARD (Target)PR179$14.6M-45.9%
HOSPITAL MENONITA DE CAYEYPR225$186.2M15.0%
SAN LUCAS PONCEPR348$141.1M9.2%
HOSPITAL DR. ALEJANDRO OTEROPR263$129.0M-1.0%
HOSPITAL MENONITA CAGUAS INCPR232$114.1M6.8%
DOCTOR CENTER HOSPITAL MANATI PR258$103.4M1.6%
MAYAGUEZ MEDICAL CENTERPR210$102.8M7.6%
HOSPITAL PAVIA SANTURCEPR156$101.9M-9.4%
UNIVERSITY DISCTRICT HOSPITALPR210$97.4M-43.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.1M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$307K+210bp18mo
Cost to Collect4.5%2.5%$292K+200bp12mo
Denial Rate Reduction12.0%6.5%$289K+198bp12mo
A/R Days Reduction5200.0%3800.0%$178K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+7bp6mo

5. EBITDA Bridge

Net Collection Rate
$307K
Cost to Collect
$292K
Denial Rate Reduction
$289K
A/R Days Reduction
$178K
Clean Claim Rate
$10K
Total EBITDA Uplift$1.1M
Current EBITDA$-6.7M
+ RCM Uplift+$1.1M
Pro Forma EBITDA$-5.6M
Current Margin-45.9%
Pro Forma Margin-38.6%
WC Released (1x)$560K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-10.3M$-33.5M0.00x-100.0%
Base (11x exit)10.0x11.0x$-10.3M$-40.2M0.00x-100.0%
Bull Case9.0x11.0x$-9.3M$-40.0M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-9.3M$-46.4M0.00x-100.0%
Bear Case11.0x10.0x$-11.4M$-35.5M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-11.4M$-42.8M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumLow occupancyAt 18.4%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 62.3% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 37 hospitals with 90-358 beds
  • Same-state prioritization (n=38)
  • Comp margins: P25=-17.6% / P50=-4.9% / P75=1.6%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.